West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.
The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.
West Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the "impact of destocking continues to moderate" but is still an overhang.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.